The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[Egtazic Acid co-treated with Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone] inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species]
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [AQP9 protein results in increased uptake of Lactic Acid]; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [AQP9 protein results in increased uptake of Selenious Acid]
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone promotes the reaction [CDKN1B protein binds to CDK4 protein] Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of CDKN1B protein
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein [Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical]; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Superoxides]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT protein]
ATM protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of COX4 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PINK1 protein binds to ATM protein] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of ATM protein
BAG2 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased lipidation of MAP1LC3B protein]; BAG2 protein inhibits the reaction [Doxorubicin inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased lipidation of MAP1LC3B protein]]
Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein] BECN1 protein inhibits the reaction [BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PINK1 protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of BNIP3L protein BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of COX4 protein]; BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Testosterone results in increased cleavage of CASP3 protein] DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form]; PGAM5 protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of COX4I1 protein [mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of COX4I1 protein; Acetylcysteine inhibits the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of COX4I1 protein]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of COX4I1 protein]]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of COX4I1 protein]
[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] affects the phosphorylation of DNM1L protein; DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form]; DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of DNM1L protein modified form
[Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and affects the localization of PINK1 protein] promotes the reaction [FKBP5 protein binds to PINK1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein [mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in decreased expression of HSPD1 protein; BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of LDHA protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [LEP protein results in increased chemical synthesis of Reactive Oxygen Species] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased susceptibility to LEP protein
BAG2 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased lipidation of MAP1LC3B protein]; BAG2 protein inhibits the reaction [Doxorubicin inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased lipidation of MAP1LC3B protein]]; Doxorubicin inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased lipidation of MAP1LC3B protein]
[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN1 protein; Acetylcysteine inhibits the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN1 protein]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN1 protein]]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN1 protein]
BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein [mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN2 protein; Acetylcysteine inhibits the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and affects the localization of MFN2 protein; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN2 protein]]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN2 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of ND1 protein Deoxyglucose inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of ND1 protein]
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]
PINK1 gene mutant form inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PINK1 protein]; PINK1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with PRKN protein] results in increased expression of PINK1 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and affects the localization of PINK1 protein] promotes the reaction [FKBP5 protein binds to PINK1 protein]; [mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased expression of PINK1 protein; Acetylcysteine inhibits the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased expression of PINK1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PINK1 protein binds to ATM protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and affects the localization of PINK1 protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and results in increased phosphorylation of PINK1 protein; PINK1 protein promotes the reaction [[[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] affects the localization of and results in increased activity of and results in increased ubiquitination of PRKN protein] which results in increased degradation of PRKN protein]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of COX4I1 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN1 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN2 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TIMM23 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TOMM20 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of VDAC1 protein]] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of PINK1 protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased stability of PINK1 protein
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of PKM protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein PRKN gene mutant form results in increased susceptibility to Carbonyl Cyanide m-Chlorophenyl Hydrazone PRKN protein results in decreased susceptibility to Carbonyl Cyanide m-Chlorophenyl Hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the expression of PRKN protein alternative form Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of PRKN protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; Acetylcysteine inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; PARK7 gene mutant form promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; PINK1 gene mutant form inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; PINK1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] affects the localization of and results in increased activity of and results in increased ubiquitination of PRKN protein] which results in increased degradation of PRKN protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with PRKN protein] results in increased expression of PINK1 protein; [mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] affects the localization of and results in increased activity of and results in increased ubiquitination of PRKN protein; Acetylcysteine inhibits the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] affects the localization of and results in increased ubiquitination of PRKN protein]; BECN1 protein inhibits the reaction [BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [AMBRA1 protein binds to PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PIK3C3 protein binds to PRKN protein]; PINK1 protein promotes the reaction [[[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] affects the localization of and results in increased activity of and results in increased ubiquitination of PRKN protein] which results in increased degradation of PRKN protein]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of COX4I1 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN1 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN2 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TIMM23 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TOMM20 protein]]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of VDAC1 protein]]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of COX4I1 protein]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN1 protein]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of MFN2 protein]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TIMM23 protein]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TOMM20 protein]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of VDAC1 protein]; Tretinoin affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the expression of PRKN protein alternative form]
[Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC2A1 protein]
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SQSTM1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of TIMM23 protein [Diethylhexyl Phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TIMM23 protein; [mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TIMM23 protein; Acetylcysteine inhibits the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TIMM23 protein]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TIMM23 protein]]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TIMM23 protein]
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Testosterone results in increased expression of TNF mRNA] Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]
[Diethylhexyl Phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TOMM20 protein; [mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TOMM20 protein; Acetylcysteine inhibits the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TOMM20 protein]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TOMM20 protein]]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of TOMM20 protein]
[Diethylhexyl Phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of VDAC1 protein; [mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of VDAC1 protein; Acetylcysteine inhibits the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of VDAC1 protein]; PINK1 protein promotes the reaction [PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of VDAC1 protein]]; PRKN protein promotes the reaction [[mono-(2-ethylhexyl)phthalate co-treated with Carbonyl Cyanide m-Chlorophenyl Hydrazone] results in increased degradation of VDAC1 protein]
Dantrolene results in decreased expression of ATF4 protein Dantrolene affects the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein]; Dantrolene promotes the reaction [Thapsigargin results in increased expression of ATF4 mRNA]
Dantrolene inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]
Dantrolene results in decreased phosphorylation of DDIT3 protein Dantrolene inhibits the reaction [Halothane results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 protein]
Dantrolene results in decreased phosphorylation of EIF2S1 protein Dantrolene inhibits the reaction [tributyltin results in increased phosphorylation of EIF2S1 protein]
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of GFAP protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of GFAP protein]
Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]] Dantrolene affects the expression of IL10 protein
Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A protein]
Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C protein]
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFL protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFL protein]
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFM protein]
Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]]; Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] which results in increased transport of Calcium]
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of VIM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of VIM protein]
Dantrolene inhibits the reaction [perfluorooctanoic acid results in increased expression of XBP1 mRNA alternative form]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of XBP1 mRNA alternative form]
Nitrofurazone results in increased expression of MYC mRNA Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of MYC mRNA]
[Nitrofurazone co-treated with POR protein co-treated with Copper] results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; Nitrofurazone inhibits the reaction [POR protein results in increased metabolism of Misonidazole]
Nitrofurazone results in increased expression of TGFA mRNA Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of TGFA mRNA]
rhosin inhibits the reaction [4-nitro-3-cresol results in increased expression of XBP1 mRNA]; rhosin inhibits the reaction [4-nitro-3-cresol results in increased expression of XBP1 protein]
AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin] AADAC protein results in increased hydrolysis of Rifampin
Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein
Rifampin results in decreased expression of ABCB11 mRNA [Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein Rifampin results in decreased expression of ABCB11 protein tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein] Rifampin results in decreased activity of ABCB11 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein
[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter] Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate Rifampin affects the activity of ABCB1 protein
ABCC2 protein affects the export of Rifampin [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein [Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA] Rifampin results in increased expression of ABCC3 mRNA Rifampin results in increased activity of ABCC3 protein
Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA]
[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA] Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein
Rifampin results in increased expression of AKR1B10 mRNA pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]
Rifampin results in decreased expression of APOB mRNA ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA] Rifampin affects the secretion of APOB protein
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein Rifampin results in decreased expression of ATM mRNA
Rifampin results in increased expression of ATP6V0A1 protein [Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein]
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein] [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein Rifampin results in decreased expression of BAX protein
Rifampin results in increased expression of BCL2 protein [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]
Rifampin results in increased expression of BCL2L1 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3 [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]
[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]
Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form] Rifampin results in increased expression of CFLAR protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA Rifampin affects the expression of CXCL10 protein
Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Rifampin results in increased activity of CYP1A1 protein Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA
NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter] Rifampin results in increased activity of CYP24A1 protein
Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene] Rifampin results in increased expression of CYP27A1 mRNA
Rifampin results in increased expression of CYP2A1 mRNA Rifampin results in increased expression of CYP2A13 mRNA Rifampin results in decreased expression of CYP2A13 mRNA
Rifampin results in increased activity of CYP2B6 protein [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein
Rifampin results in increased activity of CYP2C19 protein Rifampin results in increased expression of CYP2C29 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein Rifampin results in increased expression of and results in increased activity of CYP2C19 protein
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine] Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein Rifampin results in increased activity of CYP2C8 protein
Rifampin results in increased expression of CYP2D6 mRNA Rifampin results in increased activity of CYP2D6 protein Rifampin results in decreased expression of CYP2D22 mRNA
Rifampin results in increased activity of CYP2E1 protein Rifampin results in decreased expression of CYP2E1 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein Rifampin affects the activity of CYP3A4 protein Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] CYP3A4 protein results in decreased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein Rifampin results in decreased expression of CYP7A1 mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA] Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA
Rifampin results in increased phosphorylation of EIF2AK3 protein Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein]
Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein Rifampin results in increased expression of ERN1 mRNA
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]
Rifampin results in increased expression of FASN mRNA Rifampin affects the expression of FASN mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA]
[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA Rifampin results in increased expression of FGF19 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin results in decreased expression of G6PC1 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein Rifampin results in increased activity of GPT protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein] [Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]; Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA]
[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein
GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein] Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein [arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA
[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] [Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein
Rifampin results in decreased expression of IL6 protein Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA] Rifampin results in increased expression of IL6 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA
INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]
Rifampin results in decreased metabolism of MAP1LC3B protein ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein
Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein] Rifampin results in decreased expression of MED1 mRNA
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]
NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]
[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]
Rifampin results in increased expression of NFE2L2 protein [tanshinone co-treated with Rifampin] results in increased expression of NFE2L2 mRNA; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 protein] Rifampin results in decreased expression of NFE2L2 mRNA; Rifampin results in decreased expression of NFE2L2 protein Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein] Rifampin results in decreased activity of NFE2L2 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA Rifampin results in increased expression of NOS2 mRNA
NR1I2 protein affects the susceptibility to Rifampin Rifampin affects the localization of NR1I2 protein Rifampin results in decreased acetylation of NR1I2 protein NR1I2 protein results in increased susceptibility to Rifampin [Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of NR1I2 protein NR1I2 protein mutant form results in decreased susceptibility to Rifampin 1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein; [Ketoconazole co-treated with Rifampin] results in increased activity of NR1I2 protein; [Loperamide co-treated with Rifampin] results in increased activity of NR1I2 protein; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I2 protein; [Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; caraway oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Clove Oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; coriander oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Doxorubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; hydroxyitraconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Itraconazole promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; jasmine oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin binds to and results in increased activity of NR1I2 protein]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; lemongrass oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Miconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of amprenavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Nelfinavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Saquinavir]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased abundance of Lipids]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Oils, Volatile inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Oils, Volatile promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin binds to and results in increased activity of NR1I2 protein; Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; sulforaphane inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein]; triptolide inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] Rifampin results in increased expression of NR1I2 mRNA; Rifampin results in increased expression of NR1I2 protein Rifampin results in increased localization of NR1I2 protein [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased localization of NR1I2 protein]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] Rifampin binds to NR1I2 gene mutant form [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; Rifampin affects the localization of and results in increased activity of NR1I2 protein; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter; Rifampin binds to NR1I2 protein
Rifampin results in increased expression of NR1I3 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein Rifampin results in increased expression of NR1I3 mRNA; Rifampin results in increased expression of NR1I3 protein [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 protein
Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] Rifampin results in increased expression of NR3C1 mRNA
Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein]
[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of PCK1 mRNA
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA [Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA; [Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of PPARG mRNA alternative form; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]; Rifampin results in increased expression of and affects the localization of PPARG protein Rifampin results in increased expression of PPARG mRNA
[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline]
PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of SGK2 mRNA
Rifampin results in decreased expression of SLC10A1 mRNA Rifampin results in decreased expression of SLC10A1 protein [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 mRNA; [tanshinone co-treated with Rifampin] results in increased expression of SLC10A1 protein; tanshinone inhibits the reaction [Rifampin results in decreased expression of SLC10A1 protein] [Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1
Rifampin results in decreased expression of SLC22A1 mRNA; Rifampin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein] Rifampin results in decreased expression of SLC2A2 mRNA; Rifampin results in decreased expression of SLC2A2 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]
Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of epyrifenacil metabolite] Rifampin results in decreased activity of SLCO1A4 protein
Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased susceptibility to Docetaxel]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of epyrifenacil metabolite]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite] Rifampin inhibits the reaction [SLCO1B2 protein results in increased uptake of epyrifenacil metabolite] Rifampin results in decreased activity of SLCO1B3 protein Rifampin results in decreased expression of SLCO1B3 mRNA
Rifampin results in decreased activity of SLCO1B1 protein [Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate
Rifampin results in increased expression of SLCO2B1 mRNA Rifampin results in decreased expression of SLCO2B1 mRNA; Rifampin results in decreased expression of SLCO2B1 protein Rifampin inhibits the reaction [Dextran Sulfate results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [Lipopolysaccharides results in increased expression of SLCO2B1 mRNA]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein]
Rifampin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein modified form]; UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein]
[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA Rifampin results in increased expression of UGDH mRNA
Rifampin affects the expression of UGT1A1 mRNA Rifampin results in increased expression of UGT1A1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of UGT1A1 mRNA
triacsin C inhibits the reaction [Fatty Acids results in increased degradation of ABCA1 protein]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Phospholipids]]; triacsin C inhibits the reaction [Linoleic Acid results in increased degradation of ABCA1 protein]
triacsin C results in increased expression of and results in increased phosphorylation of JUN protein triacsin C results in increased expression of JUN mRNA
3-aminopyridine-2-carboxaldehyde thiosemicarbazone results in increased oxidation of TXN2 protein [3-aminopyridine-2-carboxaldehyde thiosemicarbazone binds to Iron] which results in increased oxidation of TXN2 protein
browse the term
